News

The Pharma Letter2d
EC approval for BMS’ subcutaneous Opdivo
The European Commission (EC) has approved a new Opdivo (nivolumab) formulation associated with a new route of administration ...
Pharmabiz2d
Bristol Myers Squibb receives European approval for subcutaneous formulation of Opdivo across multiple solid tumour indications
Bristol Myers Squibb receives European approval for subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Thursday, May 29, 2025, 15:0 ...
Viking Therapeutics: Obesity Candidates Must Prove Their Edge As Market Matures (Upgrade)
Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...
Medical Dialogues2d
Bristol Myers Squibb bags European Commission nod for Subcutaneous formulation of Opdivo across multiple solid tumor indications
Princeton: Bristol Myers Squibb has received approval from the European Commission (EC) for a new Opdivo (nivolumab) ...
ascopubs.org2d
Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ...
Carfilzomib-based induction/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk patients. This ...